Kretschmer G, Wenzl E, Schemper M, Polterauer P, Ehringer H, Marçosi L, Minar E
1st Clinic of Surgery, University of Vienna, Austria.
Lancet. 1988 Apr 9;1(8589):797-9. doi: 10.1016/s0140-6736(88)91659-5.
To examine whether anticoagulants given after autologous saphenous bypass surgery influenced patient survival 119 patients who received such a graft for obliterative arterial disease were recruited for a controlled clinical trial. Patients were randomly assigned to start, in the second postoperative week, phenprocoumon (60 patients) or no treatment (59 patients). The median duration of survival for all patients was greater than 60 months, and the 75%-quartile was 39.0 (SE of the median 3.9) months. 10 patients died in the treated group and 20 in the control group. The treated group had a greater probability of survival (p less than 0.023, Breslow; p less than 0.043, Mantel). Graft occlusions occurred in 11 patients in the treatment group and in 17 controls. When these patients were excluded from the analysis, the difference in probability of survival between the two groups remained significant (p less than 0.009, Breslow; p less than 0.013, Mantel).
为了研究自体隐静脉搭桥手术后给予抗凝剂是否会影响患者生存率,我们招募了119例因闭塞性动脉疾病接受此类移植手术的患者进行一项对照临床试验。患者被随机分配在术后第二周开始服用苯丙香豆素(60例患者)或不接受治疗(59例患者)。所有患者的生存中位数时长超过60个月,75%分位数为39.0(中位数标准误为3.9)个月。治疗组有10例患者死亡,对照组有20例患者死亡。治疗组的生存概率更高(Breslow检验,p<0.023;Mantel检验,p<0.043)。治疗组有11例患者发生移植物闭塞,对照组有17例。当将这些患者排除在分析之外时,两组之间的生存概率差异仍然显著(Breslow检验,p<0.009;Mantel检验,p<0.013)。